Matthew White
Finanzdirektor/CFO bei APIAM ANIMAL HEALTH LIMITED
Vermögen: 37 926 $ am 30.04.2024
Aktive Positionen von Matthew White
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| APIAM ANIMAL HEALTH LIMITED | Finanzdirektor/CFO | 01.08.2015 | - |
Karriereverlauf von Matthew White
Ehemalige bekannte Positionen von Matthew White
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Merck Sharp & Dohme (Australia) Pty Ltd.
 Merck Sharp & Dohme (Australia) Pty Ltd. Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Sharp & Dohme (Australia) Pty Ltd. is an Australian research-intensive biopharmaceutical company committed to saving and improving lives. The company is based in North Ryde, Australia and is dedicated to following the science to tackle some of the world's greatest health threats. MSD Australia has a long legacy of research in infectious disease and has been mobilizing its scientific expertise and experience to develop an effective response to the COVID-19 pandemic since it was first recognized. | Finanzdirektor/CFO | - | - |
Statistik
International
| Australien | 3 |
Operativ
| Director of Finance/CFO | 2 |
Sektoral
| Distribution Services | 2 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| APIAM ANIMAL HEALTH LIMITED | Distribution Services |
| Private Unternehmen | 1 |
|---|---|
Merck Sharp & Dohme (Australia) Pty Ltd.
Merck Sharp & Dohme (Australia) Pty Ltd. Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Sharp & Dohme (Australia) Pty Ltd. is an Australian research-intensive biopharmaceutical company committed to saving and improving lives. The company is based in North Ryde, Australia and is dedicated to following the science to tackle some of the world's greatest health threats. MSD Australia has a long legacy of research in infectious disease and has been mobilizing its scientific expertise and experience to develop an effective response to the COVID-19 pandemic since it was first recognized. | Health Technology |
- Börse
- Insiders
- Matthew White
- Erfahrung
